Hemogenyx Pharmaceuticals Plc Logo

Hemogenyx Pharmaceuticals Plc

HOPHF

(0.0)
Stock Price

0,00 USD

-76.33% ROA

-139.44% ROE

-0x PER

Market Cap.

17.636.255,54 USD

104.51% DER

0% Yield

0% NPM

Hemogenyx Pharmaceuticals Plc Stock Analysis

Hemogenyx Pharmaceuticals Plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Hemogenyx Pharmaceuticals Plc Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Hemogenyx Pharmaceuticals Plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Hemogenyx Pharmaceuticals Plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Sell
3 RSI Buy
4 Stoch RSI Sell

Hemogenyx Pharmaceuticals Plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Hemogenyx Pharmaceuticals Plc Revenue
Year Revenue Growth
2014 0
2015 6.845 100%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Hemogenyx Pharmaceuticals Plc Research and Development Expenses
Year Research and Development Expenses Growth
2014 0
2015 0 0%
2016 2 100%
2017 19 94.44%
2018 73 75.34%
2019 28 -160.71%
2020 114 75.44%
2021 51 -128%
2022 487 89.73%
2023 181 -169.06%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Hemogenyx Pharmaceuticals Plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 6.270
2015 174.302 96.4%
2016 331.591 47.43%
2017 390.661 15.12%
2018 402.979 3.06%
2019 429.071 6.08%
2020 623.843 31.22%
2021 1.396.852 55.34%
2022 942.352 -48.23%
2023 2.033 -46252.78%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Hemogenyx Pharmaceuticals Plc EBITDA
Year EBITDA Growth
2014 -6.270
2015 -11.019 43.1%
2016 -304.084 96.38%
2017 -686.237 55.69%
2018 -1.467.699 53.24%
2019 -1.362.090 -7.75%
2020 -1.955.031 30.33%
2021 -2.558.456 23.59%
2022 -3.422.877 25.25%
2023 -2.453 -139438.4%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Hemogenyx Pharmaceuticals Plc Gross Profit
Year Gross Profit Growth
2014 0
2015 6.845 100%
2016 -66.855 110.24%
2017 -100.481 33.47%
2018 -348.266 71.15%
2019 -421.817 17.44%
2020 -350.719 -20.27%
2021 -283.647 -23.65%
2022 -2.599.762 89.09%
2023 -1.303.088 -99.51%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Hemogenyx Pharmaceuticals Plc Net Profit
Year Net Profit Growth
2014 -6.270
2015 -180.876 96.53%
2016 -519.898 65.21%
2017 -2.361.599 77.99%
2018 -1.477.532 -59.83%
2019 -1.450.627 -1.85%
2020 -2.082.220 30.33%
2021 -5.099.228 59.17%
2022 -3.979.314 -28.14%
2023 -4.739 -83869.49%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Hemogenyx Pharmaceuticals Plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Hemogenyx Pharmaceuticals Plc Free Cashflow
Year Free Cashflow Growth
2014 -6.270
2015 79.707 107.87%
2016 -466.931 117.07%
2017 -517.236 9.73%
2018 -1.377.317 62.45%
2019 -1.211.791 -13.66%
2020 -1.971.451 38.53%
2021 -3.445.296 42.78%
2022 -3.339.549 -3.17%
2023 -1.412 -236411.97%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Hemogenyx Pharmaceuticals Plc Operating Cashflow
Year Operating Cashflow Growth
2014 -6.270
2015 79.707 107.87%
2016 -278.146 128.66%
2017 -452.979 38.6%
2018 -1.352.728 66.51%
2019 -1.199.873 -12.74%
2020 -1.798.404 33.28%
2021 -2.627.298 31.55%
2022 -2.910.604 9.73%
2023 -1.360 -213915%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Hemogenyx Pharmaceuticals Plc Capital Expenditure
Year Capital Expenditure Growth
2014 0
2015 0 0%
2016 188.785 100%
2017 64.257 -193.8%
2018 24.589 -161.32%
2019 11.918 -106.32%
2020 173.047 93.11%
2021 817.998 78.85%
2022 428.945 -90.7%
2023 52 -824794.23%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Hemogenyx Pharmaceuticals Plc Equity
Year Equity Growth
2014 43.730
2015 77.819 43.81%
2016 903.708 91.39%
2017 2.131.857 57.61%
2018 959.166 -122.26%
2019 -349.035 374.81%
2020 875.681 139.86%
2021 8.167.569 89.28%
2022 3.243.520 -151.81%
2023 2.781.006 -16.63%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Hemogenyx Pharmaceuticals Plc Assets
Year Assets Growth
2014 43.730
2015 324.653 86.53%
2016 1.047.403 69%
2017 2.395.542 56.28%
2018 2.299.599 -4.17%
2019 1.049.897 -119.03%
2020 2.664.584 60.6%
2021 8.520.410 68.73%
2022 7.092.609 -20.13%
2023 6.105.893 -16.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Hemogenyx Pharmaceuticals Plc Liabilities
Year Liabilities Growth
2014 0
2015 246.833 100%
2016 143.695 -71.78%
2017 263.685 45.51%
2018 1.340.433 80.33%
2019 1.398.932 4.18%
2020 1.788.903 21.8%
2021 352.841 -407%
2022 3.849.089 90.83%
2023 3.324.887 -15.77%

Hemogenyx Pharmaceuticals Plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-3.55
Price to Earning Ratio
-0x
Price To Sales Ratio
0x
POCF Ratio
-0
PFCF Ratio
-5.27
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
-4.96
EV to Operating CashFlow
-5.8
EV to FreeCashFlow
-5.78
Earnings Yield
-1501.44
FreeCashFlow Yield
-0.19
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
13.61
Graham NetNet
-1.7

Income Statement Metrics

Net Income per Share
-3.55
Income Quality
0.77
ROE
-1.39
Return On Assets
-0.71
Return On Capital Employed
-0.77
Net Income per EBT
1
EBT Per Ebit
1.03
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-2.74
Free CashFlow per Share
-2.75
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.04
Return on Invested Capital
-0.73
Return on Tangible Assets
-0.76
Days Sales Outstanding
0
Days Payables Outstanding
170.55
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
2.14
Inventory Turnover
0
Capex per Share
0.01

Balance Sheet

Cash per Share
1,03
Book Value per Share
2,29
Tangible Book Value per Share
1.92
Shareholders Equity per Share
2.32
Interest Debt per Share
2.68
Debt to Equity
1.05
Debt to Assets
0.48
Net Debt to EBITDA
-0.44
Current Ratio
3.33
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
5271460
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Hemogenyx Pharmaceuticals Plc Dividends
Year Dividends Growth

Hemogenyx Pharmaceuticals Plc Profile

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

CEO
Dr. Vladislav Sandler Ph.D.
Employee
17
Address
60 Gracechurch Street
London, EC3V 0HR

Hemogenyx Pharmaceuticals Plc Executives & BODs

Hemogenyx Pharmaceuticals Plc Executives & BODs
# Name Age
1 Ms. Alexis M. Sandler J.D.
Independent Co-Founder & Non-Executive Director
70
2 Mr. Ben Harber
Company Secretary
70
3 Dr. Vladislav Sandler Ph.D.
Co-Founder, Chief Executive Officer & Director
70
4 Dr. Koen Van Besien M.D., Ph.D.
Clinical Advisor & Medical Director
70

Hemogenyx Pharmaceuticals Plc Competitors